CAS: 29964-62-3; 1,4-Butylenebis(Diphenylphosphine)Palladium Dichloride

上下游产品

CAS号7688-25-7 1,4-双(二苯膦基)丁烷 | CAS号570397-18-1 dichloro-(1,2-d... | CAS号12107-56-1 (1,5-环辛二烯)氯化钯(II)

二(氰基苯)二氯化钯,1,4-双(二苯基膦)丁烷 以 甲苯 用作溶剂,化学反应 0.5H,反应生成1,4-双(二苯基膦丁烷)二氯化钯
参考文献:从丝氨酸,苏氨酸,异源苏氨酸和半胱氨酸的四酸酯衍生物合成3取代的焦谷氨酸.
标题:从丝氨酸,苏氨酸,异源苏氨酸和半胱氨酸的四酸酯衍生物合成3取代的焦谷氨酸.
摘要:据报道,通过使用在烯醇甲磺酸酯上的suzuki偶联,然后通过还原,可以从四酸酯直接获得焦谷氨酸酯的一般路线.这项工作允许直接支架从四酸酯跳到取代的焦谷氨酸酯.文库中的某些化合物显示出对革兰氏阳性细菌的适度抗菌活性.
Doi:10.1021/acs.Joc.9B01432

专利信息

专利号:US-2025101006-A1
优先权日:2022-01-31
标题:Process for the synthesis of pyrazolyl derivatives useful as anti-cancer agents
发明人：BAENZIGER MARKUS; GALLOU FABRICE; GUO FENGFENG; HÄNGGI RUDOLF; HAN ENJIAN; JORDINE GUIDO; LI JIALIANG; LIU WEIPENG; MIAO BUKEYAN; RONG SHAOFENG; SANTANDREA ERNESTO; SCHIRNER PAUL BERND; SHEN XIAODONG; WANG CAN; ZHANG HAO
权利人:NOVARTIS AG
摘要:The invention provides a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially KRAS G12C inhibitors. The present invention provides a direct enantioselective chemical manufacturing method of making Compound A, or a pharmaceutically acceptable hydrate or solvent thereof: (I). The invention provides a process for preparing Intermediate B6* comprising reacting Intermediate B4* with Intermediate B5* in an atroposelective coupling reaction, using a chiral catalyst.

专利号:WO-2025104624-A1
优先权日:2023-11-14
标题 :Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol
发明人：ALEXANDER KATY LOUISE; ANSARI ZARRIN FAZAL KHADIJA; DANIELS DAVID SYDNEY BERNARD; HASSEL LUKE HARRY; KEEN STEPHEN PHILIP; SCOTT JEREMY PETER; SCOTT REUBEN JOHN; SIMMONS JOHATHAN ANDREW; STOLL EMMA LOUISE; TRINDADE ALEXANDRE FONSECA; VICINI ANNA CHIARA
权利人:PFIZER
摘要:This disclosure relates novel methods to prepare 1,5-anhydro-3-({5-chloro-4-[4- fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2- yl}amino)-2,3-dideoxy-D-threo-pentitol, and hydrates and stereoisomers thereof, as well as intermediates, including solid forms of the intermediates, useful for the preparation of such compounds and the synthesis of said intermediates.

专利号:WO-2023086801-A1
优先权日:2021-11-09
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-2022356182-A1
优先权日:2009-03-27
标题 :Inhibitors of hepatitis c virus replication
发明人：COBURN CRAIG A; LUDMERER STEVEN W; LIU KUN; WU HAO; SOLL RICHARD; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-2024010638-A1
优先权日:2020-11-13
标题:Improved synthesis of crac channel inhibitors
发明人：STAUDERMAN KENNETH; DUNN MICHAEL; OLMSTEAD KAY
权利人:CALCIMEDICA INC
摘要:Provided herein is an improved synthetic method for the production of CRAC channel inhibitors. The synthetic method provides a method for producing highly pure CRAC channel inhibitors for clinical testing.

专利号:WO-2025128848-A1
优先权日:2023-12-12
标题:Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).